Loading
Dexrazoxane, given with the chemotherapy, cuts clinical heart failure in adults by about four fifths in pooled trials without reducing how well the chemotherapy works. Beta blockers and blood-pressure drugs given preventively protect the ejection fraction by a point or two during treatment, and in the one trial that followed patients for two years that difference had gone.
Dexrazoxane is the cardioprotectant with the strongest evidence. The 2022 Cochrane review of 13 randomised trials found that in adults it reduced clinical heart failure with a risk ratio of 0.22 (95 per cent confidence interval 0.11 to 0.43, seven studies, 1,221 adults, moderate-quality evidence), with similar benefits on combined subclinical and clinical dysfunction and no difference in overall survival. In children the evidence was weaker and the review could not pool it. The historical worry that dexrazoxane blunted tumour response or caused second cancers has not been borne out in the survival data, but it remains restricted in label and in practice to patients receiving high cumulative anthracycline doses.
Neurohormonal prevention is the approach that looked promising and then shrank. In PRADA, 130 women with early breast cancer received candesartan, metoprolol, both or placebo alongside anthracycline-containing adjuvant therapy. The ejection fraction fell 2.6 percentage points on placebo and 0.8 on candesartan, a difference of 1.8 points. Metoprolol had no effect on ejection fraction. At extended follow-up a median of 23 months after randomisation, there were no significant between-group differences, and the authors concluded that "a broadly administered cardioprotective approach may not be required in most patients with early breast cancer without preexisting cardiovascular disease". Candesartan did preserve global longitudinal strain and left ventricular volume modestly at two years.
The other levers are structural rather than pharmacological: capping the cumulative anthracycline dose, continuous rather than bolus infusion, liposomal formulations, and sparing the heart at radiotherapy planning. Treating conventional cardiovascular risk, which is the single largest determinant of whether a survivor develops heart failure, is the part most often skipped.
What comes back, and when: this record is about damage not happening rather than damage reversing. Where prevention is used, it works during the treatment window; where it is not, the recovery figures are the ones in the surveillance record alongside this one.
Dexrazoxane chelates iron and interferes with the topoisomerase-2-beta complex through which anthracyclines damage cardiomyocytes. Angiotensin blockade and beta blockade act on the neurohormonal response to injury rather than on the injury itself, which is consistent with their effect being small and not sustained after the drugs stop.
Query for this technology: (TITLE:"Protecting the heart during anthracycline treatment: dexrazoxane, beta blockers and ACE inhibitors" OR ABSTRACT:"Protecting the heart during anthracycline treatment: dexrazoxane, beta blockers and ACE inhibitors") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Protecting the heart during anthracycline treatment: dexrazoxane, beta blockers and ACE inhibitors, not a curated reading list.
Shares Late effects and survivorship toxicity, Toxicity and quality of life are undervalued, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Toxicity and quality of life are undervalued, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Toxicity and quality of life are undervalued, Diffuse large B-cell lymphoma, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Toxicity and quality of life are undervalued, Diffuse large B-cell lymphoma, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Doxorubicin, Acute lymphoblastic leukaemia, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Toxicity and quality of life are undervalued, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Toxicity and quality of life are undervalued, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Toxicity and quality of life are undervalued, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship.